First PDE-5 inhibitor recommended for use in paediatric population

Sildenafil is one of only two PDE5 inhibitors licensed for PAH.
Sildenafil is one of only two PDE5 inhibitors licensed for PAH.

The licence for Revatio (sildenafil) has been extended to include children over 1 year.

The phosphodiesterase type-5 inhibitor is approved for the treatment of pulmonary arterial hypertension (WHO class II and III) to improve exercise capacity.

Efficacy in paediatric patients has been shown in terms of improvement of exercise capacity or pulmonary haemodynamics, in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease

Before supplying Revatio for children under 20kg or patients unable to swallow tablets an oral suspension should be made using proprietary diluents (see SPC for full details).

However, Revatio IV remains unlicensed for use in patients under 18 years.

View Revatio drug record

Further Information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...